Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 10, 2014

View Archived Issues

Preclinical and phase I clinical profile of Virobay's cathepsin S inhibitors for neuropathic pain

U.S. scientists disclose new compounds for drug-resistant tuberculosis

iTeos Therapeutics collaborates with Pfizer on IDO1 and TDO2 programs

Circassia reports results from phase IIb trial of Ragweed-SPIRE vaccine

Cureveda receives NIH grants for development of VEDA-1209

MLN-7243, a first-in-class ubiquitin-activating enzyme inhibitor as a cancer therapy

QLT discloses results from phase IIa trial of QLT-091001 in impaired dark adaptation

Novel biomarkers associated with obesity and obesity-related diseases

New phase I study evaluates Cornerstone's CPI-613 for B-cell NHL

Euroscreen successfully completes phase I study of ESN-364

Phase III data demonstrate equivalence in efficacy of etanercept biosimilar in RA

Zydus Cadila launches adalimumab biosimilar in India

Lilly and Incyte report topline results from phase III trial of baricitinib

ONO-8610539: a potent coagulation factor XIa inhibitor for the treatment of DVT

Novel HCV NS3/4A inhibitors disclosed by Beijing Xintianyu Technology Development

Jiangsu Simcere Pharmaceutical divulges novel BTK inhibitors

AT-001 given U.S. orphan drug designation for X-linked myotubular myopathy

4SC reports positive topline data from phase I trial of 4SC-205 in cancer patients

First-in-class PRMT5 inhibitor as a potential therapy for mantle cell lymphoma

Mast Therapeutics provides update on development plan for vepoloxamer

Dynavax and AstraZeneca to advance AZD-1419 to phase IIa for asthma

Brilacidin receives FDA QIDP designation

Merck & Co. to acquire Cubist Pharmaceuticals

Vaccinex's anti-SEMA4D antibody VX-15/2503 is well tolerated in patients with solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 30, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...